Cyclophosphamide for Malignancies

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Malignancies+1 More
Cyclophosphamide - Drug
Eligibility
< 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test if a combination of sirolimus, celecoxib, and low-dose etoposide alternating with cyclophosphamide can shrink tumors in children who have not responded to other treatments.

Eligible Conditions
  • Malignancies

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: Baseline, End of Treatment (Up to 2 years)

Year 2
Change in radiographic response to treatment for central nervous system (CNS) tumors
Change in radiographic response to treatment for solid tumors
Number of adverse events

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Oral sirolimus, celecoxib, etoposide, and cyclophosphamide
1 of 1

Experimental Treatment

60 Total Participants · 1 Treatment Group

Primary Treatment: Cyclophosphamide · No Placebo Group · Phase 2

Oral sirolimus, celecoxib, etoposide, and cyclophosphamideExperimental Group · 4 Interventions: Cyclophosphamide, Sirolimus, Celecoxib, Etoposide · Intervention Types: Drug, Drug, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclophosphamide
FDA approved
Sirolimus
FDA approved
Celecoxib
FDA approved
Etoposide
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, end of treatment (up to 2 years)

Who is running the clinical trial?

Hyundai Hope On WheelsOTHER
6 Previous Clinical Trials
570 Total Patients Enrolled
2 Trials studying Malignancies
523 Patients Enrolled for Malignancies
Emory UniversityLead Sponsor
1,503 Previous Clinical Trials
2,706,527 Total Patients Enrolled
16 Trials studying Malignancies
1,395 Patients Enrolled for Malignancies
Cannonball Kids' Cancer FoundationUNKNOWN
2 Previous Clinical Trials
43 Total Patients Enrolled
Thomas Cash, MDPrincipal Investigator - Emory University
Medical School - New York University, Doctor of Medicine
Tufts-New England Medical Center, Residency in Physical Medicine and Rehabilitation
2 Previous Clinical Trials
110 Total Patients Enrolled

Eligibility Criteria

Age < 65 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have any of the following tumors that have experienced relapse following front-line therapy, or that are refractory to front-line therapy, and participants with tumors that carry a poor prognosis and have no known standard curative therapy.
You must have a current disease state for which there is no known curative therapy.
You have fully recovered from acute toxic effects of all prior anti-cancer therapy.
You have a performance level of greater than or equal to 50 percent.
You are less than or equal to 16 years of age at the time of screening.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 31st, 2021

Last Reviewed: November 10th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.